Home » Stocks » Allogene Therapeutics

Allogene Therapeutics, Inc. (ALLO)

Stock Price: $44.96 USD 2.34 (5.49%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 6.24B
Revenue (ttm) n/a
Net Income (ttm) -207.49M
Shares Out 138.79M
EPS (ttm) -2.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $44.96
Previous Close $42.62
Change ($) 2.34
Change (%) 5.49%
Day's Open 43.45
Day's Range 42.42 - 46.07
Day's Volume 882,012
52-Week Range 17.43 - 55.00

More Stats

Market Cap 6.24B
Enterprise Value 5.74B
Earnings Date (est) Aug 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 138.79M
Float 61.48M
EPS (basic) -2
EPS (diluted) -2.00
FCF / Share -1.84
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 11.49M
Short Ratio 6.86
Short % of Float 13.91%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 9.57
Revenue n/a
Operating Income -223.23M
Net Income -207.49M
Free Cash Flow -200.52M
Net Cash 497.22M
Net Cash / Share 3.58
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -19.41%
ROE -32.22%
ROIC -39.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (16)

Buy 12
Overweight 0
Hold 4
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(14.64% upside)
Current: 44.96
Target: 51.54
*Average 12-month price target from 13 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-202-193-
Net Income-185-212-
Shares Outstanding10128.9526.25
Earnings Per Share-1.83-7.31-
Operating Cash Flow-137-44.65-
Capital Expenditures-50.79-3.23-
Free Cash Flow-188-47.89-
Cash & Equivalents5354610.00
Net Cash / Debt5354610.00
Book Value629703-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Allogene Therapeutics, Inc.
Country United States
Employees 215
CEO David D. Chang

Stock Information

Ticker Symbol ALLO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ALLO
IPO Date October 11, 2018


Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. It is also developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. Allogene Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.